76 related articles for article (PubMed ID: 27502396)
1. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
Huber MC; Mall R; Braselmann H; Feuchtinger A; Molatore S; Lindner K; Walch A; Gross E; Schmitt M; Falkenberg N; Aubele M
BMC Cancer; 2016 Aug; 16():615. PubMed ID: 27502396
[TBL] [Abstract][Full Text] [Related]
2. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Meng S; Tripathy D; Shete S; Ashfaq R; Saboorian H; Haley B; Frenkel E; Euhus D; Leitch M; Osborne C; Clifford E; Perkins S; Beitsch P; Khan A; Morrison L; Herlyn D; Terstappen LW; Lane N; Wang J; Uhr J
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17361-5. PubMed ID: 17079488
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.
Gouri A; Dekaken A; El Bairi K; Aissaoui A; Laabed N; Chefrour M; Ciccolini J; Milano G; Benharkat S
Biomark Insights; 2016; 11():105-11. PubMed ID: 27578963
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Bae SY; Park HJ; Hong JY; Lee HJ; Lee SK
Sci Rep; 2016 Aug; 6():32258. PubMed ID: 27558531
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization.
Genua M; Ingangi V; Fonteyne P; Piontini A; Yousif AM; Merlino F; Grieco P; Malesci A; Carriero MV; Danese S
Inflamm Bowel Dis; 2016 Oct; 22(10):2390-401. PubMed ID: 27537052
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.
Wang S; Jiang L; Han Y; Chew SH; Ohara Y; Akatsuka S; Weng L; Kawaguchi K; Fukui T; Sekido Y; Yokoi K; Toyokuni S
Oncotarget; 2016 Oct; 7(43):69565-69578. PubMed ID: 27602956
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis.
Goyert N; Eeson G; Kagedan DJ; Behman R; Lemke M; Hallet J; Mittmann N; Law C; Karanicolas PJ; Coburn NG
Ann Surg; 2017 Jan; 265(1):2-10. PubMed ID: 27537539
[TBL] [Abstract][Full Text] [Related]
8. Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells-Letter.
Garona J; Alonso DF
Cancer Res; 2016 Aug; 76(16):4908. PubMed ID: 27528580
[No Abstract] [Full Text] [Related]
9. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
10. Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance.
Wang K; Xing ZH; Jiang QW; Yang Y; Huang JR; Yuan ML; Wei MN; Li Y; Wang ST; Liu K; Shi Z
Front Oncol; 2019; 9():80. PubMed ID: 30873379
[TBL] [Abstract][Full Text] [Related]
11. Human antibody V
Chu X; Li W; Hines MG; Lyakhov I; Mellors JW; Dimitrov DS
Front Oncol; 2023; 13():1194972. PubMed ID: 37876962
[TBL] [Abstract][Full Text] [Related]
12. ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer.
Li D; Hemati H; Park Y; Taftaf R; Zhang Y; Liu J; Cristofanilli M; Liu X
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345070
[TBL] [Abstract][Full Text] [Related]
13. Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA.
Zhou Y; Chen D; Xue G; Yu S; Yuan C; Huang M; Jiang L
RSC Adv; 2020 Sep; 10(57):34517-34526. PubMed ID: 35514369
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.
Alfano D; Franco P; Stoppelli MP
Front Cell Dev Biol; 2022; 10():818616. PubMed ID: 35493073
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.
Zhai BT; Tian H; Sun J; Zou JB; Zhang XF; Cheng JX; Shi YJ; Fan Y; Guo DY
J Transl Med; 2022 Mar; 20(1):135. PubMed ID: 35303878
[TBL] [Abstract][Full Text] [Related]
16. Engineered Cell-Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple-Negative Breast Cancer in Mice.
Bose RJ; Kumar US; Garcia-Marques F; Zeng Y; Habte F; McCarthy JR; Pitteri S; Massoud TF; Paulmurugan R
Adv Healthc Mater; 2022 Mar; 11(5):e2101387. PubMed ID: 34879180
[TBL] [Abstract][Full Text] [Related]
17. uPAR: An Essential Factor for Tumor Development.
Lv T; Zhao Y; Jiang X; Yuan H; Wang H; Cui X; Xu J; Zhao J; Wang J
J Cancer; 2021; 12(23):7026-7040. PubMed ID: 34729105
[TBL] [Abstract][Full Text] [Related]
18. MEK1 Inhibitor Combined with Irradiation Reduces Migration of Breast Cancer Cells Including miR-221 and ZEB1 EMT Marker Expression.
Anastasov N; Hirmer E; Klenner M; Ott J; Falkenberg N; Bao X; Mutschelknaus L; Moertl S; Combs S; Atkinson MJ; Schmid T
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33327491
[TBL] [Abstract][Full Text] [Related]
19.
Belfiore L; Saunders DN; Ranson M; Vine KL
Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32645963
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
